Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2016) 41 EP220 | DOI: 10.1530/endoabs.41.EP220

ECE2016 Eposter Presentations Cardiovascular Endocrinology and Lipid Metabolism (51 abstracts)

Comparison of serum thyroid stimulating hormone and anti-thyroid peroxidase antibody levels in euthyroid subjects with and without metabolic syndrome

Sibel Ocak Serin 1 , Hakan Kocoglu 2 , Yildiz Okuturlar 2 , Hakan Dogan 3 , Asuman Gedikbasi 2 , Irem Kirac Utku 2 , Esra Demir 2 , Ezgi Ersoy Yesil 1 , Guven Koc 1 , Tulay Eyupgiller 1 , Sema Ucak 1 & Ozlem Harmankaya 2


1Umraniye Education and Research Hospital, Istanbul, Turkey; 2Bakirkoy Dr Sadi Konuk Education and Research Hospital, Istanbul, Turkey; 3Izmir Bozyaka Education and Research Hospital, Izmir, Turkey.


Objective: The present study aimed to evaluate thyroid stimulating hormone (TSH) levels and anti-thyroid peroxidase antibodies (anti-TPOab) in euthyroid subjects with metabolic syndrome (MetS) and to compare them with healthy subjects without MetS.

Design: Study included 173 subjects consisted of 96 subjects with MetS and 77 healthy controls. Gender, age, body mass index (BMI), waist circumfrence (WC), and detailed medical history of all participants were noted. Serum insulin, glucose, ‘Homeostatic Model Assessment- Insulin Resistance’ (HOMA-IR), total cholesterol (TC-HOL), low density lipoprotein (LDL-CHOL), high density lipoprotein (HDL-CHOL), triglyceride (TG), TSH, free T4, and anti-TPOab levels were obtained.

Results: TSH and anti-TPOab levels were significantly higher in the MetS group than control group (P=0.048 and P=0.001, respectively). A ROC curve for anti-TPOab to discriminate between patients with MetS and controls was determined at ≥16.4 IU/ml (sensitivity 89.58%; specificity 80.52%; positive predictive value 85.15%; negative predictive value 86.11%; P=0.001). Odds ratio for anti-TPOab ≥16.4 IU/ml between MetS and control group were 35 547 (95% CI 14 979–84 357).

Conclusions: Serum TSH and anti-TPOab levels were significantly higher in euthyroid subjects with MetS than those without MetS. Subjects with MetS who had anti-TPOab levels ≥16.4 IU/ml had 8-9-fold risk of having higher than normal BMI; sevenfold risk of having HT; 11-fold risk of having higher than normal HOMA-IR; 2-fold higher incidence of family history of CAD; and fourfold risk of having HL.

Keywords: metabolic syndrome, anti-thyroid peroxidase antibody, thyroid stimulating hormone, cut-off

Article tools

My recent searches

No recent searches.